Market research
FENC Fennec Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 396M
- P/E ratio
- Not available
- Analyst target
- 15.6667
- Dividend yield
- Not available
- Beta
- 1.07
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA31447P1009
- Market cap
- 396M
- P/E ratio
- Not available
- Analyst target
- 15.6667
- Dividend yield
- Not available
- Beta
- 1.07
About
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FENC discussion.
5 years, 4 months ago
Fennec Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 9.9% below its 200 day moving average.
From a valuation standpoint, the stock is 37.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 835.2.
Fennec Pharmaceuticals Inc's total revenue rose by inf% to $170K since the same quarter in the previous year.
Its net income has increased by 99.5% to $-18K since the same quarter in the previous year.
Finally, its free cash flow fell by 106.5% to $-3M since the same quarter in the previous year.
Based on the above factors, Fennec Pharmaceuticals Inc gets an overall score of 3/5.